Petition To US FDA For Using NMN In Supplements Reminds Agency Of Its Reversal On NAC
Executive Summary
Natural Products Association and Alliance for Natural Health USA petition FDA to reconsider its stance on beta-nicotinamide mononucleotide. Excluding NMN from use in supplements “adversely affects the entire dietary supplement stakeholder community,” petition says.
You may also be interested in...
US Supplement Industry Left Waiting For Changes In FDA ‘Unified’ Food Programs Reorganization
“Something needed to be done” to improve FDA’s regulation of human foods supply, says Commissioner Califf says. “Dietary supplements is a whole different kettle of fish that we can discuss at a later time.”
It’s Official: US Enforcement Discretion For NAC In Supplements, And Regulatory Options For FDA
Draft guidance states enforcement discretion allowing sales of N-acetyl-L-cysteine supplements which FDA in 2020 ordered firms to halt selling due to its use as a drug ingredient. However, NAC supplements, as they have remained since 2020, were available to US consumers when draft was published.
CIR Panel’s ‘Ethereal’ Role In Cosmetics Regulation Not Clarified By MoCRA
While other legislative proposals to update US cosmetics regulations would have included FDA ingredient review or codified reviews from the CIR Expert Panel for Cosmetic Ingredient Safety, the Modernization of Cosmetic Regulations Act of 2022 does not. Panelists, industry and FDA reps discussed implications for CIR at the 5-6 March meeting of the group’s independent expert panel.